Shield pilots ironclad specialty future with Feraccru

February 8, 2017 Christoph Graener

Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeutics is looking to expand both the label and its market reach. Co-Founder and CEO Carl Sterritt reveals to Mike Ward, Informa Pharma Intelligence’s insights global director of content, his ambitions to build a West European and US-focused specialty pharma while seeking in-country specialists to partner other markets.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Carl Sterritt – CEO, Shield Therapeutics

Previous Article
Refocusing Tarveda on tumor-targeted mini-drug conjugates

In the past 18 months, Tarveda Therapeutics has been refocusing its efforts on Pentarins, its miniaturized ...

Next Article
Keryx looks to label expansion to drive Auryxia

Keryx plans to expand Aurexia’s label to treat iron deficiency in pre-dialysis patients while searching for...